FDA Approves Sanofi’s Key BTK Inhibitor for Immunology Strategy
The U.S. Food and Drug Administration (FDA) has granted approval for Sanofi’s new BTK inhibitor, a significant development for the French pharmaceutical company’s immunology strategy. This approval follows Sanofi’s acquisition…